Next Article in Journal
Cell Penetrating Peptoids (CPPos): Synthesis of a Small Combinatorial Library by Using IRORI MiniKans
Previous Article in Journal
The Role of Transport Mechanisms in Mycobacterium Tuberculosis Drug Resistance and Tolerance
Previous Article in Special Issue
The Phosphatidylinositol 3-Kinase/mTor Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration
Pharmaceuticals 2012, 5(11), 1236-1264; doi:10.3390/ph5111236
Review

The Biological Role of PI3K Pathway in Lung Cancer

1
, 2
 and 1,*
Received: 27 September 2012; in revised form: 7 November 2012 / Accepted: 14 November 2012 / Published: 20 November 2012
(This article belongs to the Special Issue PI3 Kinase Inhibitors)
View Full-Text   |   Download PDF [325 KB, uploaded 20 November 2012]   |   Browse Figure
Abstract: Lung cancer is the primary cause of cancer-related mortality worldwide and although improvements in treatment have been achieved over the last few years, long-term survival rates for lung cancer patients remain poor. Therefore, there is an imperative need for molecularly targeted agents that will achieve long-term disease control. Numerous downstream molecular pathways, such as EGF/RAS/RAF/MEK/ERK and PI3K/AKT/mTOR are identified as having a key role in the pathogenesis of various forms of human cancer, including lung cancer. PI3K/AKT/mTOR signal pathway is an important intracellular signal transduction pathway with a significant role in cell proliferation, growth, survival, vesicle trafficking, glucose transport, and cytoskeletal organization. Aberrations in many primary and secondary messenger molecules of this pathway, including mutations and amplifications, are accounted for tumor cell proliferation, inhibition of apoptosis, angiogenesis, metastasis and resistance to chemotherapy-radiotherapy. In this review article, we investigate thoroughly the biological role of PI3K pathway in lung cancer and its contribution in the development of future therapeutic strategies.
Keywords: lung cancer; PI3K pathway inhibitors; molecular pathways lung cancer; PI3K pathway inhibitors; molecular pathways
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Sarris, E.G.; Saif, M.W.; Syrigos, K.N. The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals 2012, 5, 1236-1264.

AMA Style

Sarris EG, Saif MW, Syrigos KN. The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals. 2012; 5(11):1236-1264.

Chicago/Turabian Style

Sarris, Evangelos G.; Saif, Muhammad W.; Syrigos, Kostas N. 2012. "The Biological Role of PI3K Pathway in Lung Cancer." Pharmaceuticals 5, no. 11: 1236-1264.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert